natgillin/translations-raw huggingface dataset:
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption should not take this medicinal product.
Bolniki z redko dedno intoleranco za galaktozo, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze/galaktoze naj tega zdravila ne jemljejo.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactose deficiency or glucose-galactose malabsorption should not take this medicinal product.
Bolniki z redko dedno intoleranco za galaktozo, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze/galaktoze ne smejo jemati tega zdravila.
Patients with recent acute coronary syndrome a)
Bolniki z nedavnim akutnim koronarnim sindromom a)
Patients with recent acute coronary syndrome undergoing PCI a)
Bolniki z nedavnim akutnim koronarnim sindromom a)
Patients with recurrent or progressive malignant glioma
Bolniki s ponavljajočim ali napredovalim malignim gliomom
Patients with recurrent or progressive malignant glioma
Bolniki s ponovljenim ali napredovalim malignim gliomom:
Patients with recurrent or progressive malignant glioma
Ponavljajoči se ali napredujoči maligni gliom
Patients with reduced
Bolniki z zmanjšanim delovanjem
patients with reduced liver function;
bolnikih z okvaro delovanja jeter;
Patients with reduced liver or severely reduced kidney function should start treatment with the 25 mg dose.
Bolniki z zmanjšanim delovanjem jeter ali močno zmanjšanim delovanjem ledvic morajo zdravljenje začeti s 25-miligramskim odmerkom.
Patients with refractory asthmad
Bolniki z neodzivno astmod
patients with refractory or recurrent angina associated with dynamic ST deviation, heart failure, life- threatening arrhythmias or haemodynamic instability.
To so bolniki z neodzivno ali ponavljajočo se angino pektoris, povezano z dinamično deviacijo segmenta ST, s srčnim popuščanjem, z življenjsko nevarnimi srčnimi aritmijami ali s hemodinamsko nestabilnostjo.
patients with relapsing multiple sclerosis (MS).
bolnikov s ponavljajočo se multiplo sklerozo (MS).
Patients with relapsing-remitting MS have periods when the disease is not active (remission) in between flare-ups of symptoms (relapses).
Bolniki z recidivno-remitentno MS imajo med zagoni simptomov (recidivi) obdobja, ko bolezen ni aktivna (remisija).
Patients with renal and hepatic impairments should be closely monitored.
Bolnike z okvaro ledvic in jeter je treba skrbno spremljati.
Patients with renal and/or hepatic impairment
Bolniki z okvarjenim ledvičnim in/ali jetrnijm delovanjem
Patients with renal and/or hepatic impairment
Bolniki z okvarjenim ledvičnim in/ali jetrnim delovanjem
Patients with renal and/or hepatic impairment should be monitored more closely. (see section 4.4)
Bolnike z ledvično in/ali jetrno okvaro je treba bolj skrbno spremljati. (glejte poglavje 4.4)
Patients with renal and/or hepatic impairment:
Bolniki z okvarjenim ledvičnim in/ali jetrnim delovanjem
Patients with renal impairement (see section 5.2)
Bolniki z okvaro ledvic (glejte poglavje 5.2)
Patients with renal impairment
Bolnice z ledvično okvaro
Patients with renal impairment
Bolniki z ledvično insuficienco
Patients with renal impairment
Bolniki z motnjami v delovanju ledvic
Patients with renal impairment
Odmerjanje pri bolnikih z ledvično okvaro
Patients with renal impairment
Okvara ledvic
Patients with renal impairment (see section 4.2, 4.4, and 5.2)
Bolniki z ledvično okvaro (glejte poglavja 4.2, 4.4 in 5.2)
Patients with renal impairment (see section 4.2, 4.4, and 5.2):
Bolniki z ledvično okvaro (glejte poglavja 4.2, 4.4 in 5.2)
Patients with renal impairment (Standard Cockcroft and Gault formula or glomerular filtration rate measured Tc99m DPTA serum clearance method)
Bolniki z okvarjenim delovanjem ledvic (po standardni formuli Cockcrofta in Gaulta ali hitrost glomerulne filtracije, izmerjena z metodo Tc99m-DPTA serumskega očistka)
Patients with renal impairment (Standard Cockcroft and Gault formula or Glomerular Filtration Rate measured Tc99m-DPTA serum clearance method)
Bolniki z okvarjenim delovanjem ledvic (po standardni formuli Cockcrofta in Gaulta ali hitrost glomerularne filtracije, izmerjena z metodo Tc99m-DPTA serumskega očistka)
Patients with renal impairment (Standard Cockcroft and Gault formula or Glomerular Filtration Rate measured Tc99m-DPTA serum clearance method): Pemetrexed is primarily eliminated unchanged by renal excretion.
Bolniki z okvarjenim delovanjem ledvic (po standardni formuli Cockcrofta in Gaulta ali hitrost glomerulne filtracije, izmerjena z metodo Tc99m-DPTA serumskega očistka): pemetreksed se primarno izloča nespremenjen preko ledvic.
Patients with renal impairment of a higher severity grade than mild have not been investigated.
Pri bolnikih z okvaro delovanja ledvic, ki presega blago, raziskav niso opravili.
Patients with renal impairment, 52 week placebo controlled data
Bolniki z ledvično okvaro, 52-tedenski s placebom nadzorovani podatki
Patients with renal impairment.
Bolniki z ledvično okvaro.
Patients with renal impairment:
Bolniki z ledvičnimi okvarami:
Patients with renal impairment: (Standard Cockcroft and Gault formula or Glomerular Filtration Rate measured Tc99m-DPTA serum clearance method)
Bolniki z okvarjenim delovanjem ledvic (po standardni formuli Cockcrofta in Gaulta ali hitrost glomerulne filtracije, izmerjena z metodo Tc99m-DPTA serumskega očistka)
Patients with renal impairment: (Standard Cockcroft and Gault formula or Glomerular Filtration Rate measured Tc99m-DPTA serum clearance method): Pemetrexed is primarily eliminated unchanged by renal excretion.
Bolniki z okvarjenim delovanjem ledvic (po standardni formuli Cockcrofta in Gaulta ali hitrost glomerulne filtracije, izmerjena z metodo Tc99m-DPTA serumskega očistka): pemetreksed se primarno izloča nespremenjen preko ledvic.
Patients with renal impairment: No change in dose is required for renal impairment.
Bolniki z ledvično okvaro: Pri ledvičnih okvarah ni potrebno spreminjati odmerka.
Patients with renal impairment: Rasagiline's pharmacokinetics characteristics in subjects with mild (CLcr 50-80 ml/min) and moderate (CLcr 30-49 ml/min) renal impairment were similar to healthy subjects.
Bolniki z ledvičnimi okvarami: Farmakokinetične lastnosti razagilina so bile pri osebah z blago (očistek kreatinina (CLcr) 50 – 80 ml/min) in zmerno (CLcr 30 – 49 ml/min) podobne kot pri zdravih osebah.
Patients with renal impairment: Renal impairment does not affect the pharmacokinetics of entacapone.
Bolniki z okvaro ledvic: Okvara ledvic ne vpliva na farmakokinetiko entakapona.
Patients with renal impairment: Severe renal impairment (Glomerular Filtration Rate [GFR] < 30 ml/min) did not significantly affect the pharmacokinetics of micafungin.
Bolniki z motnjami v delovanju ledvic: Hude motnje v delovanju ledvic (hitrost glomerularne filtracije GFR < 30 ml/min) niso pomembno vplivale na farmakokinetiko mikafungina.
Patients with renal impairment: Since tenofovir disoproxil fumarate can cause renal toxicity, close monitoring of renal function is recommended in any patient with mild renal impairment treated with Atripla (see sections 4.2, 4.4 and 5.2).
Bolniki z ledvično okvaro: Ker lahko dizoproksiltenofovirijev fumarat povzroči ledvično toksičnost, se priporoča skrbno nadziranje ledvične funkcije pri vseh bolnikih z blago ledvično okvaro, zdravljenih z zdravilom Atripla (glejte poglavja 4.2, 4.4 in 5.2).
Patients with renal impairment: The dose for patients with severe renal impairment (GFR < 30 ml/min/1.73 m2) is 1 mg once daily (see sections 4.3 and 5.2).
Bolniki z ledvično okvaro: odmerek za bolnike s hudo ledvično okvaro (GFR < 30 ml/min/1,73 m2) je 1 mg enkrat na dan (glejte poglavji 4.3 in 5.2).
Patients with renal impairment: The safety and efficacy have not been studied in patients with renal impairment (see section 5.2).
Bolniki z ledvično okvaro: varnosti in učinkovitosti zdravila Avastin pri bolnikih z okvaro ledvic niso proučevali (glejte poglavje 5.2).
Patients with renal impairment: The safety and efficacy of erlotinib has not been studied in patients with renal impairment (serum creatinine concentration >1.5 times the upper normal limit).
Bolniki z ledvično okvaro: varnosti in učinkovitosti erlotiniba pri bolnikih z ledvično okvaro (koncentracija kreatinina v serumu > 1,5-kratna zgornji referenčni vrednosti) niso proučevali.
Patients with renal insufficiency can also be managed by administration of Emtriva 10 mg/ml oral solution to provide a reduced daily dose of emtricitabine.
Bolniki z ledvično insuficienco so lahko zdravljeni tudi z Emtriva 10 mg/ml peroralno raztopino za zagotovitev zmanjšanega dnevnega odmerka emtricitabina.
Patients with renal insufficiency requiring dialysis have not been studied in clinical trials.
V kliničnih preskušanjih niso raziskali uporabo zdravila pri bolnikih z insuficienco ledvic, ki potrebujejo dializno zdravljenje.
Patients with renal insufficiency with estimated creatinine clearance <30 ml/ min.
Bolniki z ledvično insuficienco z ocenjenim očistkom kreatinina < 30 ml / min.
Patients with renal insufficiency with estimated creatinine clearance <30 ml/ min.
Bolniki z ledvično insuficienco z ocenjenim očistkom kreatinina < 30 ml/min.
Patients with renal or hepatic impairment
Bolnice z okvaro ledvic ali jeter
Patients with renal or hepatic impairment should be monitored closely.
Bolnike z okvaro ledvic ali jeter je treba skrbno spremljati.
Patients with renal or hepatic impairment should not be given colchicine with nelfinavir (see section 4.4).
Bolnikom z ledvično ali jetrno okvaro se ne sme dati kolhicina z nelfinavirjem (glejte poglavje 4.4).
Patients with Resistance Mutations (%)
Bolniki z virusnimi sevi, odpornimi na oseltamivir (%)
Patients with restrictive or congestive cardiomyopathy
bolniki z restriktivno ali kongestivno kardiomiopatijo,
Patients with rheumatoid arthritis, GPA or MPA must not receive MabThera if they have severe heart problems.
Bolniki z revmatoidnim artritisom, Wegenerjevo granulomatozo ali mikroskopskim poliangiitisom ne smejo prejemati zdravila MabThera, če imajo hude težave s srcem.
Patients with risk factors should be closely monitored for respiratory symptoms before and during ONIVYDE therapy.
Pri bolnikih z dejavniki tveganja je treba pred zdravljenjem z zdravilom ONIVYDE in po njem skrbno nadzirati respiratorne simptome.
Patients with schizoaffective disorder treated with this medicine should be carefully monitored for a potential switch from manic to depressive symptoms.
Bolnike s shizoafektivno motnjo, ki jemljejo to zdravilo, je treba pozorno spremljati, ker lahko pri njih pride do prehoda iz maničnih v depresivne simptome.
Patients with SEGA associated with TSC: Patients <18 years of age:
Bolniki s SEGA v povezavi s TSC: Bolniki, stari manj kot 18 let:
Patients with seizure disorders were excluded from clinical trials with BindRen.
Bolniki z motnjami z epileptičnimi napadi so bili izključenih iz kliničnih preskušanj z zdravilom BindRen.
Patients with seizures and signs/symptoms consistent with RPLS, such as hypertension, headache, decreased alertness, altered mental functioning and visual loss, including cortical blindness, should be controlled with medical management including control of hypertension.
Bolniki s konvulzijami in znaki oz. simptomi, ki se skladajo z RPLS, npr. hipertenzijo, glavobolom, zmanjšano pozornostjo, duševnimi motnjami in prizadetostjo vida (vključno s kortikalno slepoto), potrebujejo medicinski nadzor, ki naj obsega tudi obvladovanje hipertenzije.
Patients with serious infections (see section 4.4),
Bolniki z resnimi okužbami (glejte poglavje 4.4).
Patients with serious infections (see section 4.4).
Bolniki z resnimi okužbami (glejte poglavje 4.4)
Patients with serious infections (see section 4.4).
Bolniki z resnimi okužbami (glejte poglavje 4.4).
Patients with serum creatinine > 1.5 x Upper Limit of the Normal range (ULN) were excluded from the randomised study.
Bolniki s koncentracijo kreatinina v serumu > 1,5 x večjo od zgornje meje normalne vrednosti (ULN) so bili izključeni iz randomizirane študije.
Patients with serum creatinine > 1.5×ULN were excluded from the CML studies.
Bolniki se serumskim kreatininom > 1,5-kratnik ZMN so bili iz študij KML izključeni.
Patients with serum creatinine >1.5×ULN were excluded from CML studies.
Bolniki s serumskim kreatininom > 1,5-kratnik ZMN so bili iz študij KML izključeni.
Patients with serum total bilirubin > 2.0 mg/dL were excluded from clinical studies.
Bolniki s skupnim bilirubinom v serumu > 2,0 mg/dl so bili izključeni iz kliničnih študij.
Patients with severe aortic stenosis, patients with systolic blood pressure < 100 mm Hg, and patients with heart failure class NYHA III and NYHA IV.
Bolniki s hudo aortno stenozo, bolniki s sistoličnim krvnim tlakom < 100 mm Hg in bolniki s srčnim popuščanjem v razredu NYHA III ali NYHA IV.
Patients with severe asthma and COPD were shown to be able to generate sufficient inspiratory flow rate when they breathed in forcefully through the Spiromax device to enable the delivery of the required therapeutic dose to the lungs (see also section 5.1 – last five paragraphs)
Bolniki s hudo astmo in KOPB so s silovitim vdihom skozi pripomoček Spiromax dosegli ustrezno hitrost vdišnega toka, kar je omogočilo dostavo potrebnega terapevtskega odmerka v pljuča (glejte tudi poglavje 5.1, zadnjih pet odstavkov).
Patients with severe asthma may rarely present systemic hypereosinophilic syndrome or allergic eosinophilic granulomatous vasculitis (Churg-Strauss syndrome), both of which are usually treated with systemic corticosteroids.
Pri bolnikih s hudo astmo se v redkih primerih izrazi sistemski hipereozinofilni sindrom ali alergijski eozinofilni granulomatozni vaskulitis (Churg-Straussov sindrom); pri obeh sindromih je običajno zdravljenje s sistemskimi kortikosteroidi.
Patients with severe bone marrow failure should not be treated with ONIVYDE.
Bolnikov s hudo odpovedjo kostnega mozga ne smemo zdraviti z zdravilom ONIVYDE.
Patients with severe cardiovascular disease were excluded from IMBRUVICA clinical studies.
Bolniki s hudimi kardiovaskularnimi boleznimi niso bili vključeni v klinične študije zdravila IMBRUVICA.
Patients with severe depression or with depression and high levels of anxiety symptoms
Bolniki s hudo obliko depresije ali z depresijo in visoko stopnjo anksioznih simptomov
Patients with severe depression or with depression and high levels of anxiety symptoms
Bolniki s hudo obliko depresije ali zdepresijo in visoko stopnjo anksioznih simptomov
Patients with severe growth hormone deficiency in adulthood are defined as patients with known hypothalamic-pituitary pathology and at least one additional known deficiency of a pituitary hormone not being prolactin.
Bolniki s hudim pomanjkanjem rastnega hormona v odrasli dobi so opredeljeni kot bolniki z znano patologijo osi hipotalamus–hipofiza in z vsaj enim dodatno znanim pomanjkanjem hipofiznega hormona, ki ni prolaktin.
Patients with severe hepatic cirrhosis (Child-Pugh Class C) have not been studied and therefore dosing of tadalafil in these patients is not recommended .
Na bolnikih s hudo okvarjenim delovanjem jeter (razred C po Child-Pughu) študij niso opravljali, zato se uporaba tadalafila pri teh bolnikih ne priporoča.
Patients with severe hepatic cirrhosis (Child-Pugh Class C) have not been studied and therefore dosing of tadalafil is not recommended (see sections 4.4 and 5.2).
Študije na bolnikih s hudo cirozo jeter (razred C po Child-Pughu) niso bile opravljene, zato se pri njih uporaba tadalafila ne priporoča (glejte poglavji 4.4 in 5.2).
Patients with severe hepatic impairment (Child-Pugh C) have not been studied (see section 5.3).
Uporaba pri bolnikih s hudo okvaro jeter (Child-Pugh C) ni raziskana (glejte poglavje 5.3).
Patients with severe hepatic impairment (Child-Pugh C) or pre-treatment ASAT or ALAT > 5 ULN until baseline ASAT/ALAT are stabilised < 5 ULN
Pri bolnikih s hudo jetrno okvaro (Child-Pugh C) in tistim, ki so pred zdravljenjem imeli raven aspartat-aminotransferaze (ASAT) ali alanin-aminotransferaze (ALAT) > 5-krat večjo od zgornje meje normalne laboratorijske vrednosti, dokler se njuna začetna vrednost ne stabilizira na < 5-kratni zgornji meji normalne vrednosti.
Patients with severe hepatic impairment (Child-Pugh C) or pre-treatment ASAT or ALAT > 5 ULN until baseline ASAT/ALAT are stabilised < 5 ULN.
Bolniki s hudo jetrno okvaro (Child-Pugh C) in tisti, ki so pred zdravljenjem imeli raven aspartat- aminotransferaze (ASAT) ali alanin-aminotransferaze (ALAT) > 5-krat večjo od zgornje meje normalne laboratorijske vrednosti, dokler se njuna začetna vrednost ne stabilizira na < 5-kratni zgornji meji normalne vrednosti.
Patients with severe hepatic impairment (Child-Pugh C) or pre-treatment ASAT or ALAT > 5 ULN until baseline ASAT/ALAT are stabilised < 5 ULN.
Bolniki s hudo jetrno okvaro (Child-Pugh C) in tistim, ki so pred zdravljenjem imeli raven aspartat- aminotransferaze (AST) ali alanin-aminotransferaze (ALT) > 5-krat večjo od zgornje meje normalne laboratorijske vrednosti, dokler se začetna vrednost AST/ALT ne stabilizira na < 5-kratni zgornji meji normalne vrednosti.
Patients with severe hepatic impairment (Child-Pugh C) or pre-treatment ASAT or ALAT > 5 ULN until baseline ASAT/ALAT are stabilised < 5 ULN.
Pri bolnikih s hudo jetrno okvaro (Child-Pugh C) in tistim, ki so pred zdravljenjem imeli raven aspartat-aminotransferaze (ASAT) ali alanin-aminotransferaze (ALAT) > 5-krat večjo od zgornje meje normalne laboratorijske vrednosti, dokler se njuna začetna vrednost ne stabilizira na < 5-kratni zgornji meji normalne vrednosti.
Patients with severe hepatic impairment (see sections 4.2 and 5.2)
Bolniki s hudo jetrno okvaro (glejte poglavji 4.2 in 5.2)
Patients with severe hepatic impairment (with or without cirrhosis) (see section 4.2).
Bolniki s hudo jetrno okvaro (s cirozo ali brez nje) (glejte poglavje 4.2).
Patients with severe hepatic impairment have not been studied (see section 4.4) Children
Bolnikov s hudo jetrno okvaro niso raziskovali (glejte poglavje 4.4).
Patients with severe hepatic impairment have not been studied, however, Rivastigmine Actavis capsules may be used in this patient population provided close monitoring is exercised (see section 4.4 and 5.2).
Uporabe zdravila pri bolnikih s težko jetrno okvaro niso proučili, bolniki iz te populacije lahko kljub temu uporabljajo zdravilo Rivastigmin Actavis v obliki kapsul, vendar jih je treba skrbno spremljati (glejte poglavji 4.4 in 5.2).
Patients with severe hepatic impairment have not been studied, however, rivastigmine oral solution may be used in this patient population provided close monitoring is exercised (see sections 4.4 and 5.2).
Uporabe zdravila pri bolnikih s težko jetrno okvaro niso proučili, vendar se peroralna raztopina rivastigmina lahko uporablja pri tej populaciji bolnikov, če se izvaja natančno spremljanje (glejte poglavji 4.4 in 5.2).
Patients with severe hepatic impairment may have increased plasma concentrations of unbound cobimetinib compared to patients with normal hepatic function (see section 5.2).
Bolniki s hudo okvaro jeter imajo lahko v primerjavi z bolniki z normalnim delovanjem jeter zvišane koncentracije prostega kobimetiniba v plazmi (glejte poglavje 5.2).
Patients with severe hypoproteinaemia, e.g. in nephrotic syndrome,
Bolniki s hudo hipoproteinemijo, npr. pri nefrotskem sindromu.
Patients with severe hypoproteinaemia, e.g. in nephrotic syndrome.
Bolniki s hudo hipoproteinemijo, npr. pri nefrotskem sindromu.
Patients with severe immunodeficiency states, e.g.
Bolniki s hudo imunsko pomanjkljivostjo, npr.
Patients with severe immunodeficiency states, e.g.
Bolniki s stanji hude imunske pomanjkljivosti, npr.
patients with severe kidney or liver disease including that caused by cancer,
bolnikih s hudo boleznijo ledvic ali jeter, vključno s takšno, ki jo povzroča rak,
patients with severe kidney problems requiring dialysis;
bolniki s hudimi ledvičnimi težavami, ki potrebujejo dializo;
patients with severe leucopenia, neutropenia, or thrombocytopenia (low levels of white cells or platelets in the blood);
bolniki s hudo levkopenijo, nevtropenijo ali trombocitopenijo (nizkimi ravnmi belih krvnih celic ali trombocitov v krvi),
patients with severe leucopenia, neutropenia, or thrombocytopenia (low levels of white cells or platelets in the blood);
bolnikih s hudo levkopenijo, nevtropenijo ali trombocitopenijo (nizkimi ravnmi belih krvnih celic ali ploščic v krvi);
patients with severe liver disease or end-stage kidney disease requiring dialysis;
bolniki s hudim obolenjem jeter ali končno ledvično odpovedjo, pri katerih je potrebna dializa;
Patients with severe liver impairment (see sections 4.2 and 4.4).
Bolniki s hudo okvaro jeter, (glejte poglavji 4.2 in 4.4).
patients with severe liver or kidney disease; patients treated with sorivudine or similar cancer medicines such as brivudine within the last four weeks.
bolnikih z resnimi obolenji jeter ali ledvic; bolnikih, ki so bili zdravljeni s sorivudinom ali podobnimi zdravili za zdravljenje raka (kot je brivudin) v zadnjih štirih tednih.
Patients with severe liver problems or kidney problems should not take more than 10 mg in one dose.
Bolniki z resnimi obolenji jeter ali ledvic ne smejo jemati odmerkov, večjih od 10 mg.
Patients with severe lung problems or with smoker’s cough may have a higher chance of developing side effects.
Bolniki, ki imajo hude pljučne težave ali kadilski kašelj, so lahko bolj dovzetni za neželene učinke.
Patients with severe neutropenia (absolute neutrophil count < 1 X 109/L) should discontinue INVEGA and have their WBC followed until recovery.
Pri bolnikih s hudo nevtropenijo (absolutno število nevtrofilcev < 1, 0 x 109/l) je potrebno zdravljenje z zdravilom INVEGA ukiniti in spremljati število levkocitov do normalizacije.
Patients with severe neutropenia (absolute neutrophil count < 1 X 109/L) should discontinue Xeplion and have their WBC followed until recovery.
Pri bolnikih s hudo nevtropenijo (absolutno število nevtrofilcev < 1, 0 x 109/l) je potrebno zdravljenje z zdravilom Xeplion ukiniti in spremljati število levkocitov do normalizacije.
Patients with severe organ impairment should be carefully monitored for adverse reactions.
Bolnike s hudo okvaro organov je treba skrbno spremljati v zvezi z neželenimi učinki.
Patients with severe peripheral circulatory disturbance/disorders (i.e. severe forms of Raynaud’s disease or Raynaud’s syndrome) should be treated with caution.
Bolnike s hudimi motnjami oziroma boleznimi perifernega ožilja (npr. s hudimi oblikami Raynaudove bolezni ali z Raynaudovim sindromom) je treba zdraviti previdno.
Patients with severe peripheral circulatory disturbance/disorders (i.e. severe forms of Raynaud’s disease or Raynaud’s syndrome) should be treated with caution.
Pri zdravljenju bolnikov s hudimi motnjami/boleznimi perifernega krvnega obtoka (npr. hudimi oblikami Raynaudove bolezni ali Raynaudovega sindroma) je potrebna previdnost.
Patients with severe persistent asthma, chronic obstructive pulmonary disease (COPD), or are heavy smokers may be at increased risk for cancer with Simponi treatment.
Bolniki s hudo trdovratno astmo ali kronično obstruktivno pljučno boleznijo (KOPB) oziroma če veliko kadijo, imajo lahko povečano tveganje za nastanek raka po zdravljenju z zdravilom Simponi.
Patients with severe refractory eosinophilic asthma
Bolniki s hudo neodzivno eozinofilno astmo
Patients with severe renal disease will accumulate the inactive acetyl metabolite of para-aminosalicylic acid.
Pri bolnikih s hudo ledvično boleznijo se bo namreč kopičil neaktivni acetilni presnovek para- aminosalicilne kisline.
Patients with severe renal impairement (creatinine clearance <30 ml/min) should be treated with caution.
Previdnost je potrebna pri bolnikih s hudo okvaro ledvic (očistek kreatinina <30 ml/min).
Patients with severe renal impairment (CLcr
Bolniki s hudo okvaro ledvic (z očistkom kreatinina
Patients with severe renal impairment (creatinine clearance < 30 ml/min) or receiving dialysis are at greater risk of developing hypocalcaemia.
Bolniki s hudo okvaro ledvic (očistek kreatinina < 30 ml/min) ali bolniki na dializi imajo večje tveganje za pojav hipokalciemije.